- Home
- ICU
as 11-15-2024 4:00pm EST
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | DENVER |
| Market Cap: | 10.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 24.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.88 - $42.93 | Next Earning Date: | 11-13-2024 |
| Revenue: | $68,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 344.44% |
Latest SeaStar Medical Holding Corporation News
ICU Breaking Stock News: Dive into ICU Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
GlobeNewswire
4 days ago
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
11 days ago
FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis
GlobeNewswire
16 days ago
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial
GlobeNewswire
17 days ago
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
GlobeNewswire
23 days ago
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
GlobeNewswire
23 days ago
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
GlobeNewswire
25 days ago
SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial
Compare ICU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICU SeaStar Medical Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.